Bernabeu I, Alvarez-Escola C, Paniagua A, Lucas T, Pavon I, Cabezas-Agricola J
Pituitary. 2012; 16(1):101-8.
PMID: 22396133
DOI: 10.1007/s11102-012-0382-z.
Muller A, van der Lely A
Drugs. 2004; 64(16):1817-38.
PMID: 15301564
DOI: 10.2165/00003495-200464160-00007.
Racine M, Barkan A
Endocrine. 2003; 20(3):271-8.
PMID: 12721507
DOI: 10.1385/ENDO:20:3:271.
Racine M, Barkan A
Pituitary. 2003; 5(2):67-76.
PMID: 12675503
DOI: 10.1023/a:1022356313153.
Jane Jr J, Thapar K, Laws Jr E
J Neurooncol. 2002; 54(2):129-37.
PMID: 11761430
DOI: 10.1023/a:1012949214960.
Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.
Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G
J Endocrinol Invest. 1997; 20(9):537-46.
PMID: 9413808
DOI: 10.1007/BF03348016.
Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion.
Rau H, Althoff P, Schmidt K, Badenhoop K, Usadel K
Clin Investig. 1993; 71(5):372-8.
PMID: 8508007
DOI: 10.1007/BF00186626.
Long-term treatment of acromegalic patients with repeatable parenteral depot-bromocriptine.
Jaspers C, Haase R, Pfingsten H, Benker G, REINWEIN D
Clin Investig. 1993; 71(7):547-51.
PMID: 8374248
DOI: 10.1007/BF00208479.
Acromegaly. Recognition and treatment.
Jaffe C, Barkan A
Drugs. 1994; 47(3):425-45.
PMID: 7514973
DOI: 10.2165/00003495-199447030-00004.
Bromocriptine therapy in acromegaly. A long-term review of 35 cases.
Sachdev Y, Gopal K, Garg V
Postgrad Med J. 1981; 57(666):210-6.
PMID: 7027229
PMC: 2424984.
DOI: 10.1136/pgmj.57.666.210.
Bromocriptine acute effect on insulin, glucagon and growth hormone levels in acromegalic patients.
Fedele D, Molinari M, Meneghel A, Valerio A, Muggeo M, Tiengo A
J Endocrinol Invest. 1980; 3(2):149-53.
PMID: 6993548
DOI: 10.1007/BF03348242.
Gigantism and acromegaly: report of a case and review of the literature.
George A, Deen M, ATKINS F
J Natl Med Assoc. 1983; 75(11):1104, 1106-7.
PMID: 6655714
PMC: 2609777.
The endocrine profile of bromocriptine: its application in endocrine diseases.
Lancranjan I
J Neural Transm. 1981; 51(1-2):61-82.
PMID: 6455501
DOI: 10.1007/BF01664005.
Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
Ishibashi M, Yamaji T
J Clin Invest. 1984; 73(1):66-78.
PMID: 6140273
PMC: 424971.
DOI: 10.1172/JCI111208.
Recent developments in acromegaly: a review.
JADRESIC A
J R Soc Med. 1983; 76(11):947-56.
PMID: 6138432
PMC: 1439630.
DOI: 10.1177/014107688307601112.
Cushing's disease: clinical and laboratory response to bromocriptine therapy.
de Pinho M, Antunes R, Lima M, Francalanci C, Franco S
J Endocrinol Invest. 1984; 7(6):585-8.
PMID: 6099377
DOI: 10.1007/BF03349490.
Therapeutic applications of bromocriptine in endocrine and neurological diseases.
Ho K, Thorner M
Drugs. 1988; 36(1):67-82.
PMID: 3063495
DOI: 10.2165/00003495-198836010-00005.
Recent developments in the treatment of acromegaly.
Ludecke D
Neurosurg Rev. 1985; 8(3-4):167-73.
PMID: 2863781
DOI: 10.1007/BF01815441.
Medical treatment of pituitary adenomas: effects on tumor growth.
Liuzzi A, Chiodini P, Dallabonzana D, Oppizzi G, Verde G
J Endocrinol Invest. 1985; 8(3):273-81.
PMID: 2863300
DOI: 10.1007/BF03348493.
Clinical and pharmacological characterization of anomalous metoclopramide-induced growth hormone secretion in insulin-dependent diabetes mellitus.
Caviezel F, Lepore G, Maglio M, Croci M, Comi G, Morricone L
Acta Diabetol Lat. 1989; 26(2):133-45.
PMID: 2781979
DOI: 10.1007/BF02581365.
